In vitro Modified Release Studies on Melatoninergic Fluorinated Phenylalkylamides : Circumventing their Lipophilicity for Oral Administration
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets' biopolymeric materials in different ratios.
METHOD: In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin®.
RESULT: It was found that some of these systems, albeit being more lipophilic than MLT, mimic the in vitro release patterns of melatonin and Circadin®.
CONCLUSION: Moreover, a number of these derivatives were proven suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance dysfunctions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - (2024) vom: 09. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vlachou, Marilena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
In vitro dissolution studies |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0113816128304967240328065809 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371060788 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371060788 | ||
| 003 | DE-627 | ||
| 005 | 20240415234526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0113816128304967240328065809 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM371060788 | ||
| 035 | |a (NLM)38616752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vlachou, Marilena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro Modified Release Studies on Melatoninergic Fluorinated Phenylalkylamides |b Circumventing their Lipophilicity for Oral Administration |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets' biopolymeric materials in different ratios | ||
| 520 | |a METHOD: In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin® | ||
| 520 | |a RESULT: It was found that some of these systems, albeit being more lipophilic than MLT, mimic the in vitro release patterns of melatonin and Circadin® | ||
| 520 | |a CONCLUSION: Moreover, a number of these derivatives were proven suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance dysfunctions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a in vitro dissolution studies | |
| 650 | 4 | |a lipophilicity | |
| 650 | 4 | |a matrix tablets | |
| 650 | 4 | |a melatonin | |
| 650 | 4 | |a synthetic melatoninergic analogues | |
| 700 | 1 | |a Siamidi, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Protopapa, Chrystalla |e verfasserin |4 aut | |
| 700 | 1 | |a Vlachos, Michalis |e verfasserin |4 aut | |
| 700 | 1 | |a Kloutsou, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Dreliozi, Chrysoula-Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Papanastasiou, Ioannis P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g (2024) vom: 09. Apr. |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:09 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0113816128304967240328065809 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 09 |c 04 | ||